Novo Nordisk

News

FDA approves higher Wegovy dose via 4th priority voucher

The US FDA has approved a fourth product via its new National Priority Voucher Programme - a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy.

News

Generic semaglutide in India, and other weight-loss news

Novo Nordisk is facing generic semaglutide in India, Atrogi is testing a new weight loss approach, and Structure has more data with its oral GLP-1.

News

Novo rapped by FDA for not reporting drug adverse effects

Novo Nordisk has been sent a warning letter from the FDA for violations of postmarketing adverse drug experience (PADE) regulations.

News

Novo partners with Hims & Hers again, ending GLP-1 spat

Novo Nordisk and Hims & Hers have set their differences aside, agreeing to work together once again on the sale of GLP-1 agonists.

News

FDA ramps up its pushback against compounded GLP-1s

In a move that will please Novo Nordisk and Eli Lilly, the FDA sent warnings to 30 telehealth firms, accusing them of illegally marketing GLP-1 drugs.

News

Novo Nordisk plans €432m investment in Irish GLP-1 plant

Novo Nordisk invests in an Irish plant as it prepares for regulatory approvals of its Wegovy pill outside the US.

FDA approves higher Wegovy dose via 4th priority voucher

Generic semaglutide in India, and other weight-loss news

Novo rapped by FDA for not reporting drug adverse effects

Novo partners with Hims & Hers again, ending GLP-1 spat

FDA ramps up its pushback against compounded GLP-1s

Novo Nordisk plans €432m investment in Irish GLP-1 plant

Hernexeos and what’s next, with Vicky Brown

Using AI-driven synthetic personas to take your insights fur...

Novo Nordisk

Editor's Picks